FOLH1 and metastatic prostate carcinoma: One of the promising radiotracers for metastatic prostate cancer diagnosis, which has been approved by the US FDA, is [68Ga]Ga-PSMA-11, which targets prostate-specific membrane antigen (PSMA) [5,6].